Related Experiment Video
Updated: Jun 3, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups
International Journal of Clinical Practice
|March 16, 2011
Summary
Extended-release niacin/laropiprant (ERN/LRPT) effectively improves lipid profiles in patients with dyslipidemia. Its efficacy in altering low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides is consistent across diverse patient subgroups.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Extended-release niacin/laropiprant (ERN/LRPT) is indicated for primary hypercholesterolemia and mixed dyslipidemia.
- ERN/LRPT improves lipid parameters linked to atherosclerotic coronary heart disease (CHD) risk.
Purpose of the Study:
- To assess the consistency of ERN/LRPT's lipid-altering effects across various patient subgroups.
- Analysis of data from four Phase III randomized, double-blind trials.
Main Methods:
- Evaluated ERN/LRPT efficacy in subgroups based on gender, race, region, age, statin use, CHD risk, and hyperlipidemia type.
- Assessed changes in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG).
- Examined treatment effect consistency using 95% confidence intervals.
Main Results:
- ERN/LRPT significantly improved LDL-C, HDL-C, and TG levels compared to placebo/active comparator.
- Observed consistent lipid-altering effects across all analyzed patient subgroups.
Conclusions:
- ERN/LRPT is a viable therapeutic option for managing dyslipidemia.
- Demonstrated consistent efficacy in diverse patient populations.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...